Point72 Asset Management
VRDN icon

Point72 Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Point72 Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
+13,000
New +$209K ﹤0.01% 3461

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management's VRDN Position: Q2 2026 in Review

Point72 Asset Management increased its Viridian Therapeutics (VRDN) stake by 626% in Q2 2026, buying an estimated $32.6M and bringing the position to 2,343,208 shares worth $43M. The position accounts for 0.05% of the portfolio, ranked #493.

Point72 Asset Management first reported a position in VRDN in Q3 2018 and has held it in 23 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Point72 Asset Management held 2,343,208 shares of Viridian Therapeutics worth $43M as of Q2 2026.
  • Point72 Asset Management bought 2,020,372 Viridian Therapeutics shares in Q2 2026, an estimated $32.6M.
  • Viridian Therapeutics made up 0.05% of Point72 Asset Management's portfolio in Q2 2026, its #493 holding.
  • Point72 Asset Management first reported a position in Viridian Therapeutics in Q3 2018 and has held it in 23 quarters since.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.